Get started
Author

Joon Whan Rhee

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
2020 · Susan M Domchek, Sophie Postel-Vinay, et al. · The Lancet Oncology · 484
The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver
2001 · Jorge F. DiMartino, Licia Selleri, et al. · Blood · 174
PDF
The TALE Homeodomain Protein Pbx2 Is Not Essential for Development and Long-Term Survival
2004 · Licia Selleri, Jorge DiMartino, et al. · Molecular and Cellular Biology · 93
Pbx3 Deficiency Results in Central Hypoventilation
2004 · Joon Whan Rhee, Akiko Arata, et al. · American Journal Of Pathology · 89
PDF
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer
2013 · Robert. A. Burger, Mark F. Brady, et al. · Gynecologic Oncology · 71
Human CD6 possesses a large, alternatively spliced cytoplasmic domain
1995 · William H. Robinson, Henry E. Neuman de Vegvar, et al. · European Journal of Immunology · 39
Disrupted Differentiation and Oncogenic Transformation of Lymphoid Progenitors in E2A-HLF Transgenic Mice
1999 · Kevin S. Smith, Joon Whan Rhee, et al. · Molecular and Cellular Biology · 35
EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.
2023 · Yelena Y. Janjigian, Do-Youn Oh, et al. · Journal of Clinical Oncology · 29
Transformation of Bone Marrow B-Cell Progenitors by E2A-HLF Requires Coexpression of BCL-2
2002 · Kevin S. Smith, Joon Whan Rhee, et al. · Molecular and Cellular Biology · 29
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
2023 · Samuel J Klempner, Kohei Shitara, et al. · Journal of Clinical Oncology · 15
PDF
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
2024 · Zev A. Wainberg, Sae-Won Han, et al. · Journal of Clinical Oncology · 12
PDF
VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).
2019 · Andrew Tutt, Christine Stephens, et al. · Journal of Clinical Oncology · 12
DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
2020 · Shannon Neville Westin, Kathleen N. Moore, et al. · Journal of Clinical Oncology · 10
ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma.
2024 · Zev A. Wainberg, Gulam Abbas Manji, et al. · Journal of Clinical Oncology · 9
AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
2021 · Mark A. Socinski, Alexander I. Spira, et al. · Journal of Clinical Oncology · 8
VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes.
2018 · Andrew Tutt, Christine Stephens, et al. · Journal of Clinical Oncology · 8
130MO EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer
2024 · S.Y. Rha, D-Y. Oh, et al. · Annals of Oncology · 6
PDF
Abstract C007: Quemliclustat (CD73 Inhibitor) reduces adenosine-regulated NR4A gene expression and increases mPDAC inflammation in patients from the ARC-8 trial
2024 · Ji Yun Kim, Ning Wang, et al. · Cancer Research · 3
Phase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
2019 · D. Hyman, A. Hendifar, et al. · Annals of Oncology · 3
Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study
2019 · David Hyman, Andrew Hendifar, et al. · Cancer Research · 2
Abstract 3321: Real-world clinical outcome analyses in head and neck squamous cell carcinoma (HNSCC) to uncover TIGIT biology in patients treated with first-line immune checkpoint inhibitors
2025 · Meghna Das Thakur, Xiaoyong Fu, et al. · Cancer Research · 1
52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial
2024 · Ji Yun Kim, Emily Brown, et al. · Regular and Young Investigator Award Abstracts · 1
Abstract PS5-07-06: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors
2026 · A. Varkaris, M. Lipsyc-Sharf, et al. · Clinical Cancer Research
154TiP AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
2022 · Y. Lu, Y. Gong, et al. · Annals of Oncology
Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study
2019 · David Hyman, Andrew Hendifar, et al. · Clinical Trials
Works count: 28
Citation count: 1,133
H-index: 12
I10-index: 13
Year
Topic
Type